R 130
Alternative Names: R-130; R-130-OV; Recombinant oncolytic herpes simplex virus type I- Shanghai Yunying Medical TechnologyLatest Information Update: 19 Dec 2023
At a glance
- Originator Shanghai Yunying Medical Technology
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Cervical cancer; Endometrial cancer; Head and neck cancer; Osteosarcoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 12 Jul 2023 Phase-0 for Osteosarcoma (In adolescents, In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in China (Intratumoural) (NCT06171282)
- 12 Jul 2023 Shanghai Yunying Medical Technology initiates a phase 0 trial for Soft tissue sarcoma(In adolescents, In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in China (Intratumoural) (NCT06171282)
- 24 Jun 2023 Shanghai Yunying Medical Technology in collaboration with Linyi Central Hospital initiates a phase 0 trial for Solid tumors (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in China (Intratumoural; Intraperitoneal) (NCT05961111)